How the GLP-1 receptor agonist market could hit $168bn by 2033
In the past few years, there has been a significant increase in the use of GLP-1 receptor agonists as a treatment for Type 2 diabetes and obesity.
In the past few years, there has been a significant increase in the use of GLP-1 receptor agonists as a treatment for Type 2 diabetes and obesity.
What's Your Reaction?
